Sigurdur “Siggi” Olafsson
President & Chief Executive Officer
Sigurdur “Siggi” Olafsson will serve as President and Chief Executive Officer of the combined company following the close of the transaction. Since June of 2022, Mr. Olafsson has served as President, Chief Executive Officer, and member of the Board of Directors at Mallinckrodt. His qualifications to serve on the Board include more than 30 years of diverse pharmaceutical experience across branded and generic drugs, in-depth knowledge of all aspects of our business, extensive and diverse industry and managerial expertise, and a proven record of leadership to serve as President, Chief Executive Officer and director.
Before joining Mallinckrodt, Mr. Olafsson served as chief executive officer of Hikma Pharmaceuticals plc, a multinational pharmaceutical company publicly traded on the London Stock Exchange, from February 2018 to June 2022. Prior to Hikma, Mr. Olafsson served as president and chief executive officer of the Global Generic Medicines Group of Teva Pharmaceuticals, from 2014 to 2017. Before that, he was president of Actavis plc (formerly Watson Pharmaceuticals, Inc.) from 2010 to 2014, and served in other leadership roles at Actavis ehf from 2003 to 2010. Mr. Olafsson previously held a number of positions of increased responsibility in Pfizer’s Global R&D organization in the U.K. and U.S., focused on branded drug development and served as head of drug development for Omega Farma in Iceland. Mr. Olafsson previously served as a director on the boards of Hikma (2018–2022) and Pfenex Inc. (2017–2019), and as chairman of Oculis ehf. (2017–2018).
Mr. Olafsson holds a MS in pharmacy (Cand Pharm) from the University of Iceland, Reykjavik.